
BIOGRAPHICAL SKETCH

NAME in English Lichieh Julie Chu	POSITION TITLE Assistant Research Fellow, Molecular Medicine Research Center		
NAME in Chinese 朱俐潔			
EDUCATION/TRAINING			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	MM/YY	FIELD OF STUDY
Institute of Biotechnology in Medicine, National Yang-Ming University	MSc.	07/2004	Cell Biology & Immunology
Institute of Biotechnology in Medicine, National Yang-Ming University	Ph.D.	07/2011	Proteomics & Systems Biology
Molecular Medicine Research Center, Chang Gung University	Postdoctoral	07/2014	Proteomics, Genomics & Bioinformatics

A. Positions and Honors

Positions and Employment

- 06/2008 – 10/2008 **Visiting Scholar**, Dr. David R. Goodlett's Lab, University of Washington, Washington, USA
- 08/2011 – 07/2014 **Postdoctoral Fellow**, Molecular Medicine Research Center, Chang Gung University, Tao-Yuan, Taiwan, R.O.C.
- 08/2014 – *Present* **Assistant Research Fellow**, Molecular Medicine Research Center, Chang Gung University, Tao-Yuan, Taiwan, R.O.C.

Other Experience and Professional Memberships

- Taiwan Society for Mass Spectrometry (TSMS), member
- Taiwan Proteomics Society (TPS), member
- The Phi Tau Phi Scholastic Honor Society, permanent member

Honors

- National Science Council of Taiwan Undergraduate Research Program Award (2001)
- Member of the Phi Tau Phi Scholastic Honor Society (2011)

B. Selected Peer-reviewed Publications (2012-2017) (in chronological order)

Referred papers (*first/equal contribution or corresponding author)

1. **Chu LJ***, Hsu CW, Wu CC, Chen SJ, Yu JS, Chang YS, & Chang KP. **Informatics analyses and clinical verification reveal IL1RAP as a prognostic biomarker in OSCC.** (*Manuscript in preparation*)
2. Tsai YL, Tuan LH, **Chu LJ**, Lin YC, Hua KF, Wong WT, Lee SL, Lee YC, Hsu YJ, Lai JH, Chu CL, Ho LJ, Chen YC & Ka SM. (2017) **Compound K inhibits NLRP3 inflammasome in renal tubulointerstitial lesions.** (*PLoS ONE accepted*)
3. Hsiao YC*, **Chu LJ***, Chen YT, Chi LM, Chien KY, Chiang WF, Chang YT, Chen SF, Wang WS, Chuang YN, Lin SY, Chang YS, & Yu JS. (2017) **Variability assessment of 90 salivary proteins in intra-day and inter-day samples from healthy donors by multiple reaction monitoring-mass spectrometry** (*Manuscript revised by Proteomics Clin Appl*) (*Hsiao YC & Chu LJ - equal contribution*)
4. Chen TW, Lee CC, Liu H, Wu CS, Pickering CR, Huang PJ, Wang J, Chang IY, Yeh YM, Chen CD, Li HP, Luo JD, Tan BC, Chan TEH, Hsueh C, **Chu LJ**, Chen YT, Zhang B, Yang CY, Wu CC, Hsu CW, See LC, Tang P, Yu JS, Liao WC, Chiang WF, Rodriguez H, Myers JN, Chang KP, Chang YS. (2017) **APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism.** *Nat Commun.* 6;8(1):465-657.
5. Hsiao YC*, **Chu LJ***, Chen JT, Yeh TS, & Yu JS. (2017) **Proteomic profiling of the cancer cell secretome: informing clinical research.** *Expert Rev Proteomics.* 14(9):737-756. (*Hsiao YC & Chu LJ - equal contribution*)
6. Hsiao YC, Chi LM, Chien KY, Chiang WF, Chen SF, Chuang YN, Lin SY, Wu CC, **Chu LJ**, Chen YT, Chia SL, Chien CY, Chang KP, Chang YS, & Yu JS. (2017) **Development of a multiplexed assay for oral cancer candidate biomarkers using peptide immunoaffinity enrichment and targeted mass spectrometry.** *Mol Cell Proteomics.* 16(10):1829-1849.
7. Chen YT, Chen HW, Wu CF, **Chu LJ**, Chiang WF, Yu JS, & Chang YS. (2017) **Development of a Multiplexed LC-MRM MS Method of Salivary Proteins for Evaluation of Oral Cancer Biomarkers.** *Mol Cell Proteomics.* 16(5):799-811.
8. Lin YT, Chien KY, Wu CC, Chang WY, **Chu LJ**, Yeh CT, & Yu JS. (2017) **Super-SILAC mix coupled with SIM/AIMS assays for targeted verification of phosphopeptides discovered in a large-scale phosphoproteome analysis of hepatocellular carcinoma.** *J Proteomics.* 57:40-51.
9. Yu JS*, Chen YT*, Chiang WF*, Hsiao YC*, **Chu LJ***, See LC, Wu CS, Tu HT, Chen HW, Chen CC, Liao WC, Chang YT, Wu CC, Lin CY, Liu SY, Chiou ST, Cha SL, Chang KP, Chien CY, Chang SW, Chang CJ, Young JD, Pao CC, Chang YS, & Hartwell LH. (2016) **Saliva Protein Biomarkers to Detect Oral Squamous Cell Carcinoma in a High-Risk Population in Taiwan.** *Proc Natl Acad Sci USA.* 113(41):11549-54. (*Yu JS, Chen YT, Chiang WF, Hsiao YC & Chu LJ - equal contribution*)

10. Wong YH, Lin CL, Chen TS, Chen CA, Jiang PS, Lai YH, **Chu LJ**, Li CW, Chen JJ, & Chen BS. (2015) **Multiple target drug cocktail design for attacking the core network markers of four cancers using ligand-based and structure-based virtual screening methods.** *BMC Med Genomics.* 8 Suppl 4:S4.
11. Huang KY, Ku FM, Cheng WH, Lee CC, Huang PJ, **Chu LJ**, Cheng CC, Fang YK, Wu HH, & Tang P. (2015) **Novel insights into the molecular events linking to cell death induced by tetracycline in the amitochondriate protozoan *Trichomonas vaginalis*.** *Antimicrob Agents Chemother.* AAC.01779-15.
12. Huang PJ, Lee CC, Tan BC, Yeh YM, **Chu LJ**, Chen TW, Chang KP, Lee CY, Gan RC, Liu H, & Tang P. (2015) **CMPD: cancer mutant proteome database.** *Nucleic Acids Res.* 43(Database issue): D849–D855.
13. Weng RR*, **Chu LJ***, Shu HW, Wu TM, Chen MC, Chang YW, Tsai YS, Tsay YG, Goodlett DR, & Ng WV. (2013) **Large precursor tolerance database search - a simple approach for estimation of the amount of spectra with precursor mass shifts in proteomic data.** *J Proteomics.* 91:375-84 (*Weng RR & Chu LJ - equal contribution*)
14. Wu TH, **Chu LJ**, Chen TW, Lin WC, & NG WV. (2012) **Meta-analytical biomarker search of EST expression data reveals three differentially expressed candidates.** *BMC Genomics.* 13(7):S12.
15. **Chu LJ***, Yang H, Shih P, Kao Y, Tsai YS, Chen J, Huang G, Weng RR, Ting YS, Fang X, von Haller PD, Goodlett DR, & Ng WV. (2011) **Metabolic capabilities and systems fluctuations in *Haloarcula marismortui* revealed by integrative genomics and proteomics analyses.** *J Proteome Res.* 10(7):3261-3273.
16. **Chu LJ***, Chen MC, Setter J, Tsai YS, Yang H, Fang X, Ting YS, Shaffer SA, Taylor GK, von Haller PD, Goodlett DR, & Ng WV. (2011) **New structural proteins of *Halobacterium salinarum* gas vesicle revealed by comparative proteomics analysis.** *J Proteome Res.* 10(3):1170-1178.
17. Wu TH, Chang IY, **Chu LC**, Huang HC, & Ng WV. (2010) **Modularity of *Escherichia coli* sRNA regulation revealed by sRNA-target and protein network analysis.** *BMC Bioinformatics.* 11(7):S11
18. Hsu HY*, **Chu LC***, Hua KF, & Chao LK. (2008) **Heme oxygenase-1 mediates the anti-inflammatory effect of curcumin within LPS-stimulated human monocytes.** *J. Cell. Physiol.* 215: 603–612 (*Hsu HY & Chu LC are equal contribution*)
19. Hsu HY, Hua KF, Su YC, **Chu LC**, Su SC, Chiu HW, Wong CH, Chen ST, Shieh CW, Yang SS, Chen YM, & Chao LK. (2006) **Alkali-soluble polysaccharides of *Rhizoclonium riparium* alga Induce IL-1 gene expression via protein kinase signaling pathways.** *J. Agric. Food Chem.* 54: 3558-3565
20. **Chu LC***, Shih TH, & Lo NW, (2001). **Characterization of the b1,4-galactosidase activity in psychrotrophs.** *J. Chin. Soc. Anim. Sci.* 30 (4): 113

C. Research Support

Ongoing Research Support

106年度科技部補助【建置一台英雙方研究O-linked N-乙醯葡萄糖胺修飾蛋白調控NLRP3發炎體之整合型平台】

共同主持人

執行期限：105/04/01~108/03/31

計畫編號：106-2911-I-197 -501

106年度科技部補助【利用NLRP3發炎體為主之疾病專一性分析平台驗證人蔘皂苷對慢性腎臟病與代謝疾病預防與改善之功效】

共同主持人

執行期限：105/08/01~108/07/31

計畫編號：MOST 105-2628-B-197 -001 -MY3

106年度長庚醫院補助【建立膽道癌生物標誌資料庫並利用標靶蛋白定量質譜術驗證具潛力之膽汁標誌】

共同主持人

執行期限：105/07/01~108/06/30

106年度長庚醫院補助【慢性腎病急速惡化相關之生物標記-生物標識導向之研究】

共同主持人

執行期限：105/12/01~107/11/30

計畫編號：CMRPG2E0013

106年度長庚醫院補助【生物標識計畫-技術平台】

共同主持人

執行期限：105/12/01~107/11/30

計畫編號：CMRPD3B0013